Hosted on MSN

Bio-Rad outlines flat to 1% currency-neutral revenue growth for 2025 while expanding ddPCR partnerships

Earnings Call Insights: Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a ...
Seeking Alpha

Bio-Rad raises 2025 life science guidance to flat to 1% growth and expands ddPCR portfolio following Stilla acquisition

Jul. 31, 2025 9:56 PM ETBio-Rad Laboratories, Inc. (BIO) Stock, BIO.B StockAI-Generated Earnings Calls Insights ...
Seeking Alpha

Bio-Rad outlines flat to 1% currency-neutral revenue growth for 2025 while expanding ddPCR partnerships

Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a testament to the discipline and agility of our teams in what ...